The coronavirus (COVID-19) pandemic has now spread to nearly every country on the planet. The overall number of cases are greater than the number of confirmed cases. Low availability of test kits and sensitivity/specificity issues associated with a set of current kits are the key detrimental factors in timely medication. Inadequate testing capacity for SARS CoV-2 creates potential opportunities for diagnostic device companies by collaborating with other players to boost their manufacturing capacity and delivering adequate testing kits.
According to our report, diagnostic and medical device companies with capabilities of developing Molecular Assays, Immunoassays, Serological testing and Digital Solutions have great opportunities to grow in a fiercely competitive market and help countries in fighting against coronavirus (COVID-19) pandemic. Key Molecular diagnostic techniques used in the SARS CoV-2 detection kits are Reverse transcription polymerase Chain reaction (RT-PCR), Enzyme-linked Immunosorbent Assay (ELISA) and Next-generation sequencing (NGS). Artificial intelligence (AI) based systems are rapidly used for the diagnosis of COVID19 as they can easily process computed tomography (CT) images in seconds to speed up the diagnosis of COVID-19.
Key players in the domain such as Altona Diagnostics, Roche Diagnostics, Thermo Fisher Scientific, Qiagen, Euroimmun Ag and Illumina. Emerging players in the domain are Aperiomics (US), Fulgent Genetics (US), Co-Diagnostics (US), CTK Biotech (US), Medical Innovation Ventures (US), Gene Biosystems (Europe), GeneFirst (Europe), Camtech Diagnostics (APAC), SensingSelf (APAC), NanoBio Lab (APAC), Optolane Technologies (APAC) and GenBody (APAC). The report benchmarks the regulatory status of existing kits, technology used, pricing and other USPs.
The study presents opportunities for other companies such as Nector Life Sciences, Agilent technologies, Agena Bioscience and Pacific Bioscience in developing a future-fit development strategy and analytics to support their business decisions during this special period.
The key events held in concerning the development of COVID-19 diagnostics are also highlighted in the report. Further, various business models and evolving value chain will also help users in preparing their road map.
2.1 Objective of the Study
2.2 Study Scope
3.1 IEBS Approach
3.2 Research Methodology
4.1 Testing Methods
4.2 Technology Clustering
4.3 Techniques with Future Potential
5.1 Current Ecosystem
5.2 Market by Value
5.3 Market by Volume
5.4 Supply Chain Analysis
6.1 Tests Performed v/s Confirmed Cases
6.2 Inadequacy of Diagnostic Tests Worldwide
6.3 Re-occurrence of positive cases in second wave
7.1 Rapid Detection Kits
7.2 Point of Care Diagnosis
7.3 Streamlined Supply Chain
8.1 Value Chain Analysis
8.2 Integrated Manufacturers
8.3 Component Suppliers
8.4 Start-ups/Emerging Players
9.1 Altona Diagnostics
9.2 Roche Diagnostics
9.3 Thermo Fisher Scientific
9.4 Euroimmun Ag
10.3 Medical Innovation Ventures Sdn Bhd.
10.4 Gene Biosystems
10.5 GeneFirst Ltd.
10.6 Camtech Diagnostics Pte Ltd
10.7 SensingSelf Pte Ltd
11.1 Key Opportunities for Diagnostic Testing Companies
11.2 Opportunity Matrix
11.3 Potential Partners for Collaboration
12.1 Pricing and Reimbursements (Region wise)
12.2 Innovations in Testing Kits
12.3 Business Models and Evolving Value Chain
13.1 Nector Life Science
13.2 Agilent Technologies
13.3 Agena Bioscience
13.4 Pacific Bioscience